Immune Response and Risks After SARS-CoV-2 Vaccination in Hematologic Malignancies

Overview

This meta-analysis evaluated seroconversion rates and immune responses following SARS-CoV-2 vaccination in patients with hematologic malignancies. Findings indicate that approximately two-thirds of these patients achieve seroconversion after complete vaccination, which is lower than rates observed in solid cancer patients. The study also highlights the variable impact of disease subtypes and treatments on vaccine immunogenicity and the limited data on cellular immune responses and booster effects.

Background

Since the emergence of SARS-CoV-2 in late 2019, patients with hematologic malignancies such as AML and MDS have experienced higher mortality from COVID-19 compared to solid cancer patients. Vaccination reduces symptomatic infection and mortality but elicits poorer humoral immune responses in hematologic malignancy patients. Diverse disease subtypes and treatment modalities contribute to heterogeneous vaccine immunogenicity. Cellular immune responses, which may provide protection in patients with impaired humoral immunity, remain under-investigated in this population.

Data Highlights

Key Findings

• Approximately two-thirds of hematologic malignancy patients seroconvert after complete primary SARS-CoV-2 vaccination.
• Seroconversion rates in hematologic malignancies are significantly lower than the ~90% observed in solid cancer patients.
• Different hematologic malignancy subtypes and treatment modalities variably affect humoral immune responses.
• Cell-mediated immune responses are rarely evaluated but may confer protection in patients lacking seroconversion.
• Booster doses are recommended for patients with negative seroconversion, but their efficacy in hematologic malignancies remains unclear.
• Data heterogeneity and limited cellular immunity assessment highlight the need for further research.

Clinical Implications

Clinicians should recognize the reduced seroconversion rates in hematologic malignancy patients following SARS-CoV-2 vaccination and consider the impact of disease subtype and treatment on immune response. Monitoring both humoral and cellular immunity may better inform patient risk stratification. Booster vaccinations should be considered, although their benefit requires further validation in this population.

Conclusion

Patients with hematologic malignancies exhibit impaired humoral immune responses to SARS-CoV-2 vaccination compared to solid cancer patients, with variable effects based on disease and treatment factors. Enhanced evaluation of cellular immunity and booster dose efficacy is essential to optimize protective strategies in this vulnerable group.

References

1. Systematic Review and Meta-Analysis on SARS-CoV-2 Vaccination in Hematologic Malignancies, 2022